



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

19th June, 2019

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Subject: Submission of Disclosure on Related Party Transactions

In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018,- we hereby submit the attached Related Party Transactions, on consolidated basis, drawn in accordance with applicable accounting standards for period ended 31st March 2019.

Kindly take submission on record.

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

1 Relationships (during the year):

(i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company :

Glaxo Group Limited, U.K.
 GlaxoSmithKline Pte Limited, Singapore
 Eskaylab Limited, U.K.
 Burroughs Wellcome International Limited, U.K.

Holding company / ultimate holding company of the above shareholders

GlaxoSmithKline Plc, U.K.*
 GlaxoSmithKline Finance Plc, U.K.*
 Setfirst Ltd, U.K.*
 SmithKline Beecham Limited, U.K.
 Wellcome Limited, U.K.*
 The Wellcome Foundation Limited, U.K.*
 Wellcome Consumer Healthcare Limited, U.K.*

* no transactions during the year

(ii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the year:

GlaxoSmithKline Asia Private Limited, India
 GlaxoSmithKline Brasil Ltda, Brazil*
 GlaxoSmithKline Consumer Healthcare Limited, India
 GlaxoSmithKline Biologicals S.A., Belgium
 GlaxoSmithKline Pharmaceuticals S.A., Belgium
 GlaxoSmithKline Services Unlimited, U.K.
 Glaxo Operations UK Limited, U.K.
 GlaxoSmithKline Export Limited, U.K.
 GlaxoSmithKline Latin America S.A.*
 GlaxoSmithKline Pakistan Limited, Pakistan*
 GlaxoSmithKline Research & Development Ltd, U.K.
 GlaxoSmithKline Pte Limited, Singapore*
 GlaxoSmithKline Corporate Centre, U.S.A.*
 GlaxoSmithKline Philippines Inc., Philippines*
 GlaxoSmithKline Australia Pty Limited, Australia*
 GlaxoSmithKline Trading Services Limited, Ireland
 GlaxoSmithKline Limited, Hong Kong*
 GlaxoSmithKline South Africa (Pty) Ltd, South Africa
 GlaxoSmithKline LLC, U.S.A.*
 GlaxoSmithKline Pharmaceutical Nigeria Limited, Nigeria
 Stiefel India Private Limited, India
 Glaxo Wellcome Ceylon Ltd., Sri Lanka*
 US GMS Financial Services, U.S.A.*
 GlaxoSmithKline Inc, Philadelphia
 GlaxoSmithKline Manufacturing SPA, Italy*
 GlaxoSmithKline Intellectual Property Limited
 Chiron Behring Vaccines Private Ltd, India (upto February 28, 2019)

(iii) Directors and members of GSK India Leadership Team :

Directors:

Mr. A. Vaidheesh #
 Ms. P. Thakur # (w.e.f. January 1, 2018)
 Mr. A. Aristidou # (upto December 31, 2017)*
 Mr. R. Krishnaswamy #
 Mr. N. Kaviratne
 Mr. P. Bhide
 Ms. A. Bansal
 Mr. A.N. Roy
 Mr. D.S. Parekh (upto March 31, 2019)
 Mr. D. Sundaram
 Mr. R.R. Bajaj (upto July 24, 2019)
 Mr. S. Williams (w.e.f. April 7, 2017)
 Mr. M. Jones (w.e.f. April 7, 2017 upto July 24, 2018)

GSK India Leadership Team:

Mr. A. Nadkarni (w.e.f. April 17, 2017)
 Mr. K. Hazari (upto May 31, 2018)
 Mr. R. D'souza (w.e.f. April 17, 2017)
 Mr. R. Bartaria (upto August 31, 2018)
 Mr. S. Dheri
 Ms. S. Choudhary
 Mr. S. Webb (w.e.f. January 17, 2018 upto January 31, 2019)
 Ms. V. Desai (upto May 16, 2017)
 Mr. V. Balakrishnan (w.e.f. March 20, 2017 upto September 21, 2018)
 Mr. B. Kotak (w.e.f. June 14, 2017)
 Mr. A. Iyer (w.e.f. October 13, 2017)
 Ms. M. Priyam (w.e.f. July 27, 2017)
 Ms. D. Jakate (w.e.f. February 19, 2018)
 Mr. S. Balasubramanian (w.e.f. October 01, 2018)
 Mr. N. Hindia (w.e.f. June 01, 2018)
 Mr. G. Kotian (w.e.f. October 01, 2018)
 Mr. N. Sudrik (w.e.f. October 01, 2018)

Also member of GSK India Leadership Team


* no transactions during the year

2 The following transactions were carried out with the related parties in the ordinary course of business:

(i) Dividend paid to parties referred to in item 1(i) above:

(Rupees in lakhs)

	Year ended March 31, 2019
Glaxo Group Limited, U.K.	106,69.84
GlaxoSmithKline Pte Limited, Singapore	83,30.70
Eskaylab Limited, U.K.	20,58.00
Burroughs Wellcome International Limited, U.K.	11,76.00



Related Party disclosures (continued)

(ii) Details relating to parties referred to in items 1(i) and 1(ii) above:

(Rupees in lakhs)

	Holding company/ultimate holding company 1(i)	Other companies in the GSK Group 1(ii)
	Year ended March 31, 2019	Year ended March 31, 2019
1 Purchase of materials/traded goods	-	465,35.29
2 Sale of materials/sale of products	-	18.54
3 Purchase of Intangible assets	-	9,45.00
4 Expenses recharged to other companies	70.55	60,02.39
5 Expenses recharged by other companies	-	41,71.84
6 Manufacturing charges recovered	-	9,22.62
7 Clinical research and data management recoveries	-	7,71.88
8 Liabilities written back	-	23,14.00
9 Employee benefit liabilities transferred to a related party	-	12.52
10 Outstanding receivables at the period end	-	67,02.64
11 Outstanding payables at the period end	-	65,03.24

Note: Transactions and balances with its own subsidiary are eliminated upon consolidation

(iii) Details relating to persons referred to in item 1(iii) above:

(Rupees in lakhs)

	Year ended March 31, 2019
1 Remuneration/commission/sitting fees	29,75.30
2 Payments under the long-term incentive plan	3,63.74

